Literature DB >> 12490619

Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide.

Kesheng Zhao1, Guoxiong Luo, Guo-Min Zhao, Peter W Schiller, Hazel H Szeto.   

Abstract

Oligopeptides are generally thought to have poor permeability across biological membranes. Recent studies, however, suggest significant distribution of [Dmt1]DALDA (Dmt-D-Arg-Phe-Lys-NH2; Dmt is 2',6'-dimethyltyrosine), a 3+ net charge opioid peptide, to the brain and spinal cord after subcutaneous administration. Peptide transporters (PEPT1 and PEPT2) play a major role in the uptake of di- and tripeptides across cell membranes, but their ability to transport tetrapeptides is not clear. The purpose of this study was to determine whether [Dmt1]DALDA can translocate across Caco-2 cell monolayers and whether PEPT1 plays a role in the uptake process. Our results show that [3H][Dmt1]DALDA can readily translocate across Caco-2 cells, with a permeability coefficient estimated to be 1.24 x 10(-5) cm/s. When incubated with Caco-2 cells, [3H][Dmt1]DALDA was detected in cell lysates by 5 min. The internalization of [Dmt1]DALDA was confirmed visually with a fluorescent [Dmt1]DALDA analog (H-Dmt-D-Arg-Phe-dnsDap-NH2; dnsDap is beta-dansyl-L-alpha,beta-diaminopropionic acid). The uptake of [3H][Dmt1]DALDA was concentration-dependent but temperature- and pH-independent. Treatment with diethylpyrocarbonate (DEPC) inhibited [14C]glycine-sarcosine uptake but increased [3H][Dmt1]DALDA uptake 34-fold. These findings suggest that PEPT1 is not involved in [Dmt1]DALDA internalization. [Dmt1]DALDA uptake was also observed in SH-SY5Y, human embryonic kidney 293, and CRFK cells, and was independent of whether the cells expressed opioid receptors. The efflux of [3H][Dmt1]DALDA from Caco-2 cells was temperature-dependent and was inhibited by DEPC, but was not affected by verapamil, an inhibitor of P-glycoprotein. These data show transcellular translocation of a highly polar 3+ charge tetrapeptide and suggest that [Dmt1]DALDA may not only distribute across the blood-brain barrier but also it may even have reasonable oral absorption.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12490619     DOI: 10.1124/jpet.102.040147

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  48 in total

Review 1.  Mitochondria as a target in treatment.

Authors:  Marie-Céline Frantz; Peter Wipf
Journal:  Environ Mol Mutagen       Date:  2010-06       Impact factor: 3.216

Review 2.  Transport systems for opioid peptides in mammalian tissues.

Authors:  Vadivel Ganapathy; Seiji Miyauchi
Journal:  AAPS J       Date:  2005-12-29       Impact factor: 4.009

Review 3.  Cell-permeable, mitochondrial-targeted, peptide antioxidants.

Authors:  Hazel H Szeto
Journal:  AAPS J       Date:  2006-04-21       Impact factor: 4.009

Review 4.  First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.

Authors:  Hazel H Szeto
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 5.  Mitochondrial medicine for aging and neurodegenerative diseases.

Authors:  P Hemachandra Reddy
Journal:  Neuromolecular Med       Date:  2008-06-20       Impact factor: 3.843

Review 6.  Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development.

Authors:  Hazel H Szeto; Peter W Schiller
Journal:  Pharm Res       Date:  2011-06-03       Impact factor: 4.200

7.  Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.

Authors:  Steven Ballet; Debby Feytens; Koen Buysse; Nga N Chung; Carole Lemieux; Suneeta Tumati; Attila Keresztes; Joost Van Duppen; Josephine Lai; Eva Varga; Frank Porreca; Peter W Schiller; Jozef Vanden Broeck; Dirk Tourwé
Journal:  J Med Chem       Date:  2011-03-17       Impact factor: 7.446

Review 8.  Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications.

Authors:  Nadezda Apostolova; Victor M Victor
Journal:  Antioxid Redox Signal       Date:  2015-03-10       Impact factor: 8.401

Review 9.  Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.

Authors:  Hana M Zegallai; Grant M Hatch
Journal:  Mol Cell Biochem       Date:  2021-01-07       Impact factor: 3.396

10.  Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease.

Authors:  Ana Navarro; Alberto Boveris
Journal:  Front Aging Neurosci       Date:  2010-09-01       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.